Effects of Parmigiano Reggiano on Muscle and Inflammatory Response to Eccentric Resistance Training in Older Adults

Sponsor
University of Padova (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04861857
Collaborator
(none)
24
1
2
16
1.5

Study Details

Study Description

Brief Summary

Aging is associated with the loss of muscle mass and function (sarcopenia) and reduced tissue regenerative capacity.

Eccentric exercise (ECC) is a model of RET that can be used with the elderly, due to the ability of the muscle to combine high muscle strength production with low energy cost. ECC contractions are significantly more damaging to the muscles and produce greater muscle strength, for these reasons there is a greater risk of inducing muscle damage before the muscle is able to adapt.

Parmigiano Reggiano (PR) has some peculiar bromatological characteristics. The proteins contained in it, and in particular the potentially bioactive peptide sequences, can rapidly provide the amino acids necessary to promote muscle growth and repair during exercise. Furthermore, PR can be an important source of fatty acids, of which a significant amount of short-chain fatty acids (SCFA) which are known to have important clinical effects on body composition and metabolic health and can have a systemic anti-inflammatory effect.

Therefore, the central hypothesize is that PR consumed while being engaged in a RET can provide more energy substrates and improve muscle recovery, redcue inflammatory markers and improve lipid metabolism. To date, no studies have studied its function on recovery from exercise nor in the elderly.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Parmigiano Reggiano
  • Dietary Supplement: Whey Protein
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
24 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Effects of Parmigiano Reggiano on Muscle and Inflammatory Response to 12 Weeks of Eccentric Resistance Training in Older Adults
Anticipated Study Start Date :
May 1, 2021
Anticipated Primary Completion Date :
Mar 31, 2022
Anticipated Study Completion Date :
Aug 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Parmigiano Reggiano

participants will consume 50 g/die of the dietary supplement and undergo to eccentric exercise training 3 times/week

Dietary Supplement: Parmigiano Reggiano
subjects will receive 50 g/die of the dietary supplement

Active Comparator: Whey Protein

participants will consume 20 g/die of the dietary supplement and undergo to eccentric exercise training 3 times/week

Dietary Supplement: Whey Protein
subjects will receive 20 g/die of the dietary supplement

Outcome Measures

Primary Outcome Measures

  1. Leg lean Mass [Change from baseline to up to 12 weeks]

    kg of lean mass measured via DEXA

Secondary Outcome Measures

  1. inflammatory marker: IL-6 [Change from baseline to up to 12 weeks]

    levels of plasma IL-6 (mg/dL)

  2. cholesterol [Change from baseline to up to 12 weeks]

    levels of plasma cholesterol (mg/dL)

Eligibility Criteria

Criteria

Ages Eligible for Study:
60 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • age >60 years

  • BMI >18 and <30 kg/m2

  • stable body weight in the past 3 months

  • valid medical certifacate for practice of physical activity

Exclusion Criteria:
  • diabetes or pre-diabetes as for ADA guidelines

  • chronic diseases (cardiovascular, liver, respiratory, cancer, etc)

  • acute inflammatory status

  • regular practice of intense physical activity (>2 sessions/week)

  • treatment with steroids in the past 3 months

  • regular use of >50g/die of Parmigiano Reggiano

Contacts and Locations

Locations

Site City State Country Postal Code
1 Nutrition and Exercise Lab, DSB, University of Padova Padova Italy 35131

Sponsors and Collaborators

  • University of Padova

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Padova
ClinicalTrials.gov Identifier:
NCT04861857
Other Study ID Numbers:
  • PaRMA.2
First Posted:
Apr 27, 2021
Last Update Posted:
May 5, 2021
Last Verified:
Jan 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 5, 2021